ACHN Share Price

Open 4.16 Change Price %
High 4.20 1 Day -0.08 -1.90
Low 4.08 1 Week -0.07 -1.67
Close 4.12 1 Month -0.06 -1.44
Volume 1561295 1 Year -3.44 -45.50
52 Week High 9.95
52 Week Low 3.78
ACHN Important Levels
Resistance 2 4.23
Resistance 1 4.19
Pivot 4.13
Support 1 4.05
Support 2 4.01
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
AAPL 119.97 0.78%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
AMCF 0.06 50.00%
LOCM 0.09 50.00%
REXX 0.74 42.31%
CWEI 145.25 39.69%
CLSN 0.51 30.77%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 4.95 22.83%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

ACHN Technical Analysis 5
As on 17th Jan 2017 ACHN Share Price closed @ 4.12 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 7.29 & Strong Sell for SHORT-TERM with Stoploss of 4.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACHN Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ACHN Other Details
Segment EQ
Market Capital 720848960.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.achillion.com
ACHN Address
ACHN
300 George Street
New Haven, CT 06511
United States
Phone: 203-724-6000
Fax: 203-624-7003
Interactive Technical Analysis Chart Achillion Pharmaceuticals, Inc. ( ACHN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Achillion Pharmaceuticals, Inc.
ACHN Business Profile
Achillion Pharmaceuticals, Inc., incorporated on August 17, 1998, is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.